Share This Page
Drug Price Trends for NDC 68308-0748
✉ Email this page to a colleague
Average Pharmacy Cost for 68308-0748
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| IMVEXXY 10 MCG MAINTENANCE PAK | 68308-0748-08 | 25.78001 | EACH | 2025-12-17 |
| IMVEXXY 10 MCG STARTER PACK | 68308-0748-18 | 25.78017 | EACH | 2025-12-17 |
| IMVEXXY 10 MCG MAINTENANCE PAK | 68308-0748-08 | 25.79054 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68308-0748
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 68308-0748
Introduction
NDC: 68308-0748 refers to a specific pharmaceutical product identified within the National Drug Code system, which standardizes drug listings in the United States. Precise details about this NDC—such as drug name, formulation, strength, and manufacturer—are essential to understanding its market dynamics. However, without this specific data, this analysis focuses on general principles influencing market valuation and price trends applicable to similar drugs within its class, considering factors like patent status, therapeutic category, competitive landscape, and regulatory environment.
Drug Identification and Therapeutic Category
Assuming NDC 68308-0748 pertains to a biological or small-molecule therapy—typically indicated by the NDC's lower-middle numeric range—estimating market potential requires identification of its therapeutic class. For example, if it falls within oncology, immunology, or rare disease treatments, market size, patent protections, and reimbursement frameworks can vary considerably.
Note: Precise market insights depend on the clinical indication, which guides demand, competitive intensity, and pricing strategies.
Market Landscape Overview
1. Current Market Size and Demand
The U.S. pharmaceutical market for specialty drugs, particularly in rare diseases or biologics, continues to expand, driven by targeted therapies and personalized medicine initiatives. According to IQVIA data, specialty drug sales outpaced traditional pharmaceuticals, accounting for approximately 50% of total prescription drug expenditure in recent years[1].
Assuming our drug addresses an unmet medical need or has demonstrated superior efficacy, initial adoption typically begins within niche markets, gradually expanding as indications broaden and supply chains mature.
2. Competitive Environment
Key considerations include:
- Patent Status: Patent protection prolongs exclusivity, maintaining pricing power. Patent expirations, however, introduce generic or biosimilar competition, exerting downward pressure on prices.
- Market Penetration & Reimbursement: Reimbursement policies from CMS and private insurers significantly influence market access and pricing negotiations.
- Regulatory Approvals: FDA accelerated approvals or orphan drug designations can expedite market entry and influence valuation by ensuring exclusivity or premium pricing.
3. Regulatory and Reimbursement Dynamics
Reimbursement frameworks directly impact the pricing trajectory:
- Value-Based Pricing: Increasingly adopted to justify premium prices based on clinical benefit.
- Pricing Caps: Some payers impose maximum allowable prices, constraining revenue potential.
- Coverage and Prior Authorization: May delay or restrict patient access, affecting market size.
Price Projections
1. Current Price Benchmarks
For substantial biologics or specialty drugs, list prices can range from $10,000 to over $100,000 per year per patient, contingent upon treatment complexity, manufacturing costs, and market exclusivity.
Example: Oncology biologics such as trastuzumab (Herceptin) have historically listed at approximately $70,000–$100,000 annually[2].
2. Short-term (1-3 years) Price Trends
Initially, if patent protection and market exclusivity are intact, the drug can command high premiums — potentially $50,000 to $150,000 annually — dictated by therapeutic benefit, competitive landscape, and reimbursement acceptance.
Price increases within the first few years may mirror inflation rates or reflecting expanded indications. However, increased payer resistance and biosimilar entry could suppress growth.
3. Long-term (4-10 years) Price Trends
As patents expire:
- Competition from biosimilars: Expected to reduce prices by 20-50%, depending on market acceptance.
- Market saturation: Will cap price growth, possibly leading to price erosion.
- Regulatory changes: Payer policies favoring cost-effective therapies may further suppress prices.
Projected compounded annual growth rates (CAGR) for innovative therapies suggest a stabilization or slight decline over the long term, assuming biosimilar competition and negotiated discounts.
4. External Factors Influencing Pricing
- Healthcare Policy Changes: Potential reforms targeting drug cost transparency can influence net prices.
- Manufacturing Costs: Advances in bioprocessing may reduce production expenses, potentially leading to price reductions.
- Market Expansion: Entry into international markets, especially emerging economies, could open additional revenue streams, albeit often at lower prices.
Implications for Investors and Stakeholders
Stakeholders should monitor patent life cycles, regulatory approvals, and market penetration indicators to refine pricing strategies. Early-stage market access negotiations and real-world evidence collection can support sustained premium pricing.
Key Market Drivers and Risks
| Drivers | Risks |
|---|---|
| Innovation and demonstrated clinical superiority | Patent cliffs leading to biosimilar entry |
| Favorable reimbursement policies | Payer resistance to high prices |
| Regulatory incentives (or fast-track approvals) | Market saturation and competition |
| Expanding indications | Manufacturing challenges or cost escalations |
Conclusion
The pricing landscape for NDC 68308-0748 hinges on its therapeutic value, patent life, regulatory environment, and competitive pressures. Short-term premiums are justifiable with exclusivity and proven efficacy, but long-term sustainability depends on strategic positioning in an evolving marketplace characterized by biosimilar proliferation and value-based reimbursement schemes.
Key Takeaways
- Market Size & Demand: Specialty drugs in niche therapeutic areas command high initial prices, with significant growth potential if backed by strong clinical data.
- Pricing Strategy: Maintaining a premium price requires demonstrating unique benefits; expiration of patents likely diminishes prices through biosimilar competition.
- Regulatory & Reimbursement Influences: Active engagement with policymakers and payers enhances market access and pricing stability.
- Long-term Outlook: Price erosion is inevitable post-patent expiry; diversification into international markets and indication expansion can offset declines.
- Investment Consideration: Continuous surveillance of patent status, regulatory milestones, and competitive actions is critical for accurate price projection and strategic planning.
FAQs
1. What factors primarily determine the pricing of NDC: 68308-0748 in the current market?
Pricing is driven by therapeutic uniqueness, patent protection, manufacturing costs, regulatory approval status, and payer reimbursement policies.
2. How will biosimilar competition impact the price of this drug over time?
Biosimilar entries typically lead to a 20-50% reduction in prices, with market share redistribution affecting the original product’s profitability.
3. What are the key considerations for forecasting the drug’s future market share?
Patent expirations, clinical effectiveness, market acceptance, regulatory developments, and competitive dynamics govern future market share.
4. How do regulatory incentives influence the drug’s pricing trajectory?
Designations like orphan drug status and expedited review pathways can extend exclusivity, enabling higher prices during initial commercialization phases.
5. In what ways can international expansion affect long-term pricing projections?
Entering international markets broadens revenue streams and can mitigate domestic price erosion; however, local pricing regulations and reimbursement rates vary widely.
References
[1] IQVIA. "The Impact of Specialty Drugs on U.S. Healthcare." 2022.
[2] GoodRx. "Cost of Trastuzumab (Herceptin)." 2023.
More… ↓
